All cannabis‐based and cannabinoid medications should be subjected to the rigorous scrutiny of the Federal Food and Drug Administration (FDA) regulatory process. This process provides important protections for patients, making medications available only when they: 1) are standardized by identity, purity, potency and quality; 2) are accompanied by adequate directions for use in the approved medical indication; and 3) have risk/benefit profiles that have been defined in well‐controlled clinical trials.
Links
[1] http://www.asam.org/docs/publicy-policy-statements/1role_of_phys_in_med_mj_9-10.pdf?sfvrsn=0
[2] http://www.rethinkpot.org/tags/asam
[3] http://www.rethinkpot.org/tags/potency
[4] http://www.rethinkpot.org/tags/cannabis